Acer Therapeutics Inc
F:P6NA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Fudan Microelectronics Group Co Ltd
OTC:SFDMY
|
CN |
|
Storskogen Group AB (publ)
STO:STOR B
|
SE |
Acer Therapeutics Inc
Inventory
Acer Therapeutics Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acer Therapeutics Inc
F:P6NA
|
Inventory
$4.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$13.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
Acer Therapeutics Inc
Glance View
Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2006-09-01. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.
